Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for PM359 for the Treatment of Chronic Granulomatous Disease
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Heliostar Presents Q2 2026 Financial and Operating Results with Record Gold Production and Cash Balance
EraNova Announces Positive Preliminary Economic Assessment for the Adanac Molybdenum Project: After-Tax NPV of $714.4 Million and 23.5% IRR
